ACE and COVID-19: Finally, it has been demonstrated that Pirfenidone inhibits the AT1R/p38 MAPK pathway, decreases angiotensin II, and angiotensin II type 1 receptor, as well as angiotensin-converting enzyme (ACE) expression, which will both protect cells from developing fibrosis (LXR-α), and limit entrance of the COVID-19-SARS virus into cells by decreasing ACE receptors (2, 27, 28).